Jornay PM (Methylphenidate HCl) Patent Expiration, LOE Window & CMS Spending

Jornay PM (Methylphenidate HCl) by Ironshore A Wholly Owned Sub Of Collegium: FDA Orange Book LOE 2032-03-23, 7 AB generics, $108.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIronshore A Wholly Owned Sub Of Collegium
FDA Application & PathwayN209311 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-03-23
Orange Book Patents (*PED Extensions)16 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$108.9M
2024 Medicare Part D Spend$1.4M
2024 Medicaid Spend$107.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel